Company: PACB
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001299130-25-000168
Chunk: 62

Company: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 62
---
 rate and estimated subordinated credit spread for a CCC credit rating.Changes in the estimated fair value of the contingent consideration liability during the nine months ended September 30, 2025 were as follows:(In thousands)Level 3Beginning balance as of December 31, 2024$18,700 Change in estimated fair value(18,700)Ending balance as of September 30, 2025$— Changes to the fair value are recorded as change in fair value of contingent consideration in the condensed consolidated statements of operations and comprehensive loss.Cash, Cash Equivalents, Restricted Cash, and InvestmentsThe following tables summarize our cash, cash equivalents, restricted cash, and investments:As of September 30, 2025(In thousands)AmortizedCost GrossunrealizedgainsGrossunrealizedlossesFairValueCash and cash equivalents$56,467 $— $— $56,467 Investments:Corporate debt securities 23,298 123 (1)23,420 U.S. government & agency securities218,475 309 (17)218,767 Total investments 241,773 432 (18)242,187 Total cash, cash equivalents and investments $298,240 $432 $(18)$298,654 Short-term restricted cash$300 $— $— $300 Long-term restricted cash$1,532 $— $— $1,532 As of December 31, 2024(In thousands)AmortizedCostGrossunrealizedgainsGrossunrealizedlossesFairValueCash and cash equivalents$55,370 $— $— $55,370 Investments:Corporate debt securities46,746 184 (25)46,905 U.S. government & agency securities287,393 418 (155)287,656 Total investments334,139 602 (180)334,561 Total cash, cash equivalents and investments$389,509 $602 $(180)$389,931 Short-term restricted cash$690 $— $— $690 Long-term restricted cash$1,532 $— $— $1,532 

Q3 Fiscal 2025 Form 10-Q11

The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of September 30,